These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia. Wiseman GA; Leigh BR; Erwin WD; Sparks RB; Podoloff DA; Schilder RJ; Bartlett NL; Spies SM; Grillo-López AJ; Witzig TE; White CA Cancer Biother Radiopharm; 2003 Apr; 18(2):165-78. PubMed ID: 12804042 [TBL] [Abstract][Full Text] [Related]
7. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122 [TBL] [Abstract][Full Text] [Related]
8. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma. Alcindor T; Witzig TE Curr Treat Options Oncol; 2002 Aug; 3(4):275-82. PubMed ID: 12074764 [TBL] [Abstract][Full Text] [Related]
9. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study. Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS; Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803 [TBL] [Abstract][Full Text] [Related]
10. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. Witzig TE; Flinn IW; Gordon LI; Emmanouilides C; Czuczman MS; Saleh MN; Cripe L; Wiseman G; Olejnik T; Multani PS; White CA J Clin Oncol; 2002 Aug; 20(15):3262-9. PubMed ID: 12149300 [TBL] [Abstract][Full Text] [Related]
11. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma. Marcus R Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024 [TBL] [Abstract][Full Text] [Related]
12. Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma. Krasner C; Joyce RM Curr Pharm Biotechnol; 2001 Dec; 2(4):341-9. PubMed ID: 11762415 [TBL] [Abstract][Full Text] [Related]
13. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Wiseman GA; Gordon LI; Multani PS; Witzig TE; Spies S; Bartlett NL; Schilder RJ; Murray JL; Saleh M; Allen RS; Grillo-López AJ; White CA Blood; 2002 Jun; 99(12):4336-42. PubMed ID: 12036859 [TBL] [Abstract][Full Text] [Related]
14. Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma. Vaklavas C; Meredith RF; Shen S; Knox SJ; Micallef IN; Shah JJ; LoBuglio AF; Forero-Torres A Cancer Biother Radiopharm; 2013 Jun; 28(5):370-9. PubMed ID: 23530878 [TBL] [Abstract][Full Text] [Related]
15. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Wiseman GA; White CA; Witzig TE; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Grillo-López AJ Clin Cancer Res; 1999 Oct; 5(10 Suppl):3281s-3286s. PubMed ID: 10541376 [TBL] [Abstract][Full Text] [Related]
16. Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma. Shen S; Forero A; Meredith RF; Shah JJ; Knox SJ; Wiseman GA; Usrey ME; Lobuglio AF J Nucl Med; 2010 Jan; 51(1):150-7. PubMed ID: 20008989 [TBL] [Abstract][Full Text] [Related]
17. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody. Wagner HN; Wiseman GA; Marcus CS; Nabi HA; Nagle CE; Fink-Bennett DM; Lamonica DM; Conti PS J Nucl Med; 2002 Feb; 43(2):267-72. PubMed ID: 11850494 [TBL] [Abstract][Full Text] [Related]
18. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Esmaeli B; McLaughlin P; Pro B; Samaniego F; Gayed I; Hagemeister F; Romaguera J; Cabanillas F; Neelapu SS; Banay R; Fayad L; Wayne Saville M; Kwak LW Ann Oncol; 2009 Apr; 20(4):709-14. PubMed ID: 19150940 [TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Chinn PC; Leonard JE; Rosenberg J; Hanna N; Anderson DR Int J Oncol; 1999 Nov; 15(5):1017-25. PubMed ID: 10536187 [TBL] [Abstract][Full Text] [Related]
20. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Zinzani PL; Tani M; Pulsoni A; Gobbi M; Perotti A; De Luca S; Fabbri A; Zaccaria A; Voso MT; Fattori P; Guardigni L; Ronconi S; Cabras MG; Rigacci L; De Renzo A; Marchi E; Stefoni V; Fina M; Pellegrini C; Musuraca G; Derenzini E; Pileri S; Fanti S; Piccaluga PP; Baccarani M Lancet Oncol; 2008 Apr; 9(4):352-8. PubMed ID: 18342572 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]